Market Intelligence, Clinical Progress, and High-Purity Reagents for TCR-T, TCR-mimetic Antibody, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HLA-A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-A*02:01 (or Custom Allele) ECD-Fc-B2M Complex High purity (>95%), Endotoxin <1EU/ug, Sequence Verified, Peptide-loaded |
View HLA-A Products |
| Gene Delivery | HLA-A Promoter-ORF Lentivirus Full-length ORF for stable cell line construction, CMV or EF1a promoter options |
View HLA-A Products |
| Co-Receptor | Beta-2 Microglobulin (B2M) Recombinant Protein HEK293 Expressed, Essential for HLA-A folding and stability |
View B2M Products |
| Benchmark Ab | Anti-HLA-A (W6/32 Equivalent Sequence) Pan-HLA Class I recognizer, recombinant positive control |
View HLA-A Products |
| Validator | HLA-A siRNA Set (3 specific sequences) For knockdown verification and HLA-loss escape studies |
View HLA-A Products |
| Related Target B2M | B2M Light chain of HLA class I complex; required for surface expression and peptide presentation |
View B2M Products |
| Related Target HLA-B | HLA-B Alternative class I heavy chain; allelic competition and cross-presentation studies |
View HLA-B Products |
| Related Target HLA-E | HLA-E Non-classical class I; innate immune checkpoint with NKG2A, relevant to HLA-I downregulation contexts |
View HLA-E Products |
| Related Target CD8 | CD8 Co-receptor for MHC I, critical for T-cell activation assays and avidity measurement |
View CD8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allele-Specific Peptide Presentation (e.g., A02:01 vs A11:01) | Allele-Specific Proteins Available: A02:01, A11:01, A*24:02 with matched peptide loading (Sequence Verified by Mass Spec) |
| B2M-Dependent Conformational Stability | Pre-Complexed Format: HLA-A heavy chain + B2M + peptide delivered as stable heterodimer; no assembly required |
| Endotoxin Sensitivity in Immune Assays | Ultra-Low Endotoxin: <0.1 EU/ug standard; <0.01 EU/ug available for T-cell activation assays |
| Cell Surface Expression Validation | Lentivirus Premade Particles: HEK293T packaging, high titer (>10^8 TU/ml), codon-optimized for mammalian expression |
| Cross-reactivity Screening (Allo-recognition) | Homolog panel proteins (HLA-A, HLA-B, HLA-C) strictly verified by mass spec for off-target profiling |
| Specificity Controls (False Positives) | Validated siRNA included for specificity checks; clinical benchmark antibody W6/32 biosimilar included |
Global Clinical Landscape & Future Outlook
The HLA-A targeting space is transitioning from diagnostic tissue typing to therapeutic intervention. With the FDA approval of tebentafusp (Immunocore) targeting gp100-HLA-A*02:01 in uveal melanoma, the industry has validated TCR-like bispecifics against peptide-HLA complexes. The current R&D wave focuses on TCR-T cell therapies for solid tumors, off-the-shelf allogeneic platforms requiring HLA-A knockouts, and neoantigen discovery pipelines dependent on accurate HLA-A binding prediction. A major challenge remains overcoming the low density of pHLA complexes on tumor cells and ensuring absolute specificity to avoid cross-reactivity with healthy tissues. Tumor escape via HLA-A loss-of-heterozygosity (LOH) or B2M downregulation is driving combination therapies with epigenetic modulators (e.g., HDAC inhibitors) and IFN-γ agonists. As personalized cancer vaccines advance, demand for recombinant HLA-A monomers and tetramers for immune monitoring is accelerating exponentially. The next wave will extend into infectious disease (HBV, HPV, CMV) targeting viral peptide-HLA-A complexes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-mimetic Bispecifics | Immunocore, Immatics, AstraZeneca | Uveal Melanoma, Gastric Cancer, Solid Tumors (PRAME, NY-ESO-1) | Peptide-HLA Binding Validation (Need allele-specific HLA-A/B2M/peptide complexes) |
| Autologous TCR-T | Adaptimmune, Iovance, Kite (Gilead) | Sarcoma, NSCLC, Melanoma | Tetramer Staining Controls (Need high-avidity HLA-A tetramers with specific peptides) |
| Allogeneic Cell Therapy | Cellectis, CRISPR Therapeutics, ArsenalBio | AML, Lymphoma (Off-the-shelf) | HLA-A Knockdown/Out Validation (Need potent siRNA, lentiviral ORF, and knockout cell lines) |
| Personalized Cancer Vaccine | BioNTech, Moderna, Gritstone | Multi-solid Tumors | Immunogenicity Screening (Need HLA-A allele panels for binding affinity assays) |
| TCR-mimetic ADCs | Emerging biotechs | Oncology | Internalization Assay (Need HLA-A+ target cell lines via lentivirus for conjugate uptake) |
Molecular Differentiation & Assay Strategy
Achieving best-in-class therapeutics (TCR-mimetic antibody or TCR-T) against HLA-A requires differentiation across four critical dimensions:
1. Affinity & Specificity Natural TCRs bind pHLA with low affinity (1-100 µM), whereas therapeutic candidates require nM to pM affinity. However, excessive affinity risks cross-reactivity with self-peptide-HLA complexes. Strategy: Use multi-concentration SPR/BLI to measure affinity and perform peptide exchange assays to confirm strict peptide dependency. TarMart supplies sequence-verified HLA-A heavy chains with custom peptide loading and a homolog panel (HLA-A, -B, -C) for cross-reactivity screening.
2. Delivery & Stability TCR-mimetic antibodies must recognize native membrane-bound conformation. High-concentration formulation (>100 mg/mL) stability is a development hurdle. Strategy: Use lentivirus-generated stable cell lines (retaining glycosylation and membrane localization) for flow-based binding validation. TarMart offers premade lentiviral particles for rapid cell line construction with natural post-translational modifications.
3. Internalization Efficiency For ADC or drug conjugate modalities, pHLA complex internalization kinetics must be evaluated, as not all epitopes internalize effectively. Strategy: Engineer reporter cell lines with fluorescence tags via lentivirus and perform confocal co-localization. TarMart lentiviral ORF can incorporate tags for internalization tracking.
4. Safety: Off-target Toxicity Mitigation HLA-A is broadly expressed on normal tissues, so the safety window is extremely narrow. The therapeutic must distinguish peptide-loaded HLA-A from free HLA-A and avoid cross-reactivity with HLA-B/C presenting similar peptides. Strategy: Validate target dependency by HLA-A siRNA knockdown (signal should diminish), counter-screen against HLA-B/C-overexpressing cells, and test healthy tissue microarrays. TarMart provides siRNA sets and homolog proteins for multi-dimensional counterscreening.
Related Targets for Cross-sell
- B2M: Light chain of HLA class I; essential for folding and surface expression. B2M mutations are a common immune escape mechanism. Customers targeting HLA-A almost always require B2M reagents for refolding or knockout validation.
- HLA-B: Co-expressed with HLA-A, competes for peptide repertoire. Important for pan-class I off-target screening when developing multi-specific TCRs.
- HLA-E: Upregulated when classical class I (HLA-A/B/C) is downregulated (tumor escape). Acts as an innate immune checkpoint via NKG2A. Recommended for combination therapy studies (HLA-A target + NKG2A inhibitor).
- CD8: T-cell co-receptor critical for TCR-pHLA avidity measurements and T-cell activation assays. Useful as a control in co-culture experiments.